Clinical trials: Secondary Stroke
Atherosclerotic Cardiovascular Disease
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease…
- Trial name
- SIRIUS (NCT05974345)
- Testing
- Inclisiran sodium, Ezetimibe, Evolocumab
- Where
- France
- Volunteers
- 204,691 people
- Sponsor
- Novartis Pharmaceuticals
Carotid Artery Stenosis
Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting
Remote limb ischemic preconditioning (RIPC) has neuro-protective and anti-inflammatory effects on ischemia- reperfusion injury. As the extent of its effect is unknown, the investigators will use clinical outcome, serum…
- Trial name
- NCT01654666
- Testing
- Remote ischemic preconditioning, Carotid Artery Stenting
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Ji Xunming
Ischemic Stroke
Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance
The purpose of this study is to determine whether Magnetic Resonance Imaging may predict the risk of Intracerebral Hemorrhage for patients with ischemic stroke who receive indefinite oral anticoagulation
- Trial name
- HERO (NCT02238470)
- Testing
- oral anticoagulants
- Where
- 30 sites in Italy, Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Acute Ischemic Stroke
An Application That Can Provide Early Warning of Temperature Health Risks and Give Protective Suggestions or Personalized Suggestions Based on Patients' Own Secondary Prevention Risk Factors Was Applied to Intervene, and the Intervention Effect of APP on Stroke Recurrence Risk Was Analyzed
This study employs individualized temperature health risk early warning and risk factor management interventions for stroke, and explores their actual intervention effects.
- Trial name
- NCT06904664
- Testing
- Individualized temperature health risk early warning and risk factor management, Temperature health risk early warning, Risk factor management
- Volunteers
- 10,184 people
- Sponsor
- Xuanwu Hospital, Beijing
Stroke, Embolism
Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients
This is local prospective multicenter observational non-interventional local study. Primary study objective is investigate and describe prescription pattern of neurologists in secondary stroke or non-CNS (non-Central Nervous…
- Trial name
- NEURO-XAR (NCT01925755)
- Testing
- Rivaroxaban ( Xarelto, BAY59-7939)
- Where
- Russia
- Volunteers
- 209 people
- Sponsor
- Bayer
Stroke
Stroke Survival in Municipalities: Impact of Geographic Proximity to First- and Second-degree Relatives
Our key objective will be to investigate if geographic proximity to first- and second-degree relatives has an influence on post-acute stroke survival and use of health and social services.
- Trial name
- NCT04072120
- Where
- Norway
- Volunteers
- 7,400,000 people
- Sponsor
- University of Oslo
Patent Foramen Ovale
Device Closure Versus Medical Therapy for Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale (DEFENSE-PFO)
Background and hypothesis: The appropriate treatment strategy for secondary stroke prevention in patients with cryptogenic stroke and patent foramen ovale (PFO) remains challenging.
- Trial name
- NCT01550588
- Testing
- Device closure, Standard medical treatment
- Where
- 4 sites in South Korea
- Volunteers
- 210 people
- Sponsor
- Jae-Kwan Song
Stroke, Obesity
Secondary Prevention of Stroke Through Non-drug Therapeutic Weight Reduction
SCENARIO is a trial to investigate the role of non-drug weight reduction in secondary prevention of stroke. It is a single-blinded, randomized, controlled multicentre trial with two arms.
- Trial name
- SCENARIO (NCT01721538)
- Testing
- Weight reduction program, Lecture on healthy nutrition
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Philipps University Marburg
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer
Hypertension, Stroke
TEC4Home Stroke - Feasibility of Home Telemonitoring Technology in Managing Hypertension Among Stroke/TIA Patients
This study will test the feasibility of a home blood pressure telemonitoring (HBPTM) system in patients with minor stroke or TIA in the past year.
- Conditions
- Hypertension, Stroke, Blood Pressure, High, Systolic Hypertension
- Trial name
- NCT03712033
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Vancouver Coastal Health Research Institute
Stroke
Iron Chelation in the Prevention of Secondary Degeneration After Stroke
Stroke is a major cause of disability over the world. While acute therapies have made huge progresses, the number of survivors leaving with clinical consequences of stroke is increasing.
- Trial name
- CHEL-IC (NCT05111821)
- Testing
- Magnetic Resonance Imaging (MRI), Deferiprone treatment
- Where
- 2 sites in France
- Volunteers
- 11 people
- Sponsor
- University Hospital, Bordeaux
Ischemic Stroke
Quality Improvement in Stroke Prevention (QUISP)
Is a secondary prevention intervention, focused on implementation of standardized pre-printed discharge orders for hospitalists, effective at increasing utilization of the following evidence-based treatments 6 months after…
- Trial name
- NCT00328640
- Testing
- Optimal treatment
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- University of California, San Francisco
Stroke
Long-term Follow-up After Stroke (The LAST-long Trial)
Despite the improved treatment of acute stroke over the past decades, those suffering from stroke still are at an increased risk of functional and cognitive decline in the long term.
- Trial name
- LAST-long (NCT03859063)
- Testing
- Intervention, Control
- Where
- 4 sites in Norway
- Volunteers
- 301 people
- Sponsor
- Norwegian University of Science and Technology
Stroke
Efficiency Study of Traditional Chinese Medicine (TCM) Versus Western Medicine (WM) on Ischemic Stroke
Complex project of Traditional Chinese Medicine (TCM) with Western Medicine (WM) project under stroke unit mode contrast,assuming that the efficiency of TCM on early rehabilitation and secondary prevention of ischemic stroke is…
- Trial name
- NCT00843765
- Testing
- acupuncture, massage and basic TCM treatment, rehabilitation and WM basic treatment
- Where
- China
- Volunteers
- 1,151 people
- Sponsor
- China Academy of Chinese Medical Sciences
Stroke, Transient Ischemic Attack
China Stroke Secondary Prevention Trial
The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in China to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke…
- Trial name
- CSSPT (NCT01317849)
- Testing
- Folic Acid, Vitamin B6, Vitamin B12
- Where
- China
- Sponsor
- Xijing Hospital
Stroke, Transient Ischemic Attack
Comprehensive Post-Acute Stroke Services
The purpose of this pragmatic study is to investigate whether implementation of a comprehensive post-acute stroke service model that integrates Early Supported Discharge (ESD) and Transitional Care Management (TCM) for stroke…
- Trial name
- COMPASS (NCT02588664)
- Testing
- COMPASS Intervention
- Where
- 40 sites in United States
- Volunteers
- 6,024 people
- Sponsor
- Wake Forest University Health Sciences
Stroke, Stroke, Ischemic
Telerehabilitation With Aims to Improve Lower Extremity Recovery Post-Stroke (TRAIL-RCT)
The purpose of this study is to compare the effectiveness of a 4-week lower extremity telerehabilitation protocol with aims to improve lower extremity function to a 4-week attention-controlled education program on lower extremity…
- Conditions
- Stroke, Stroke, Ischemic, Stroke Hemorrhagic, Cerebral Injury
- Trial name
- TRAIL-RCT (NCT04908241)
- Testing
- TRAIL, EDUCATION
- Where
- 5 sites in Canada
- Volunteers
- 96 people
- Sponsor
- University of British Columbia
Ischemic Stroke, Transient Ischemic Attack
Treat Stroke to Target
The aim of this study is the evaluation of two usual care strategies after stroke or TIA : achieved target LDL-C of 100 mg/dL (+/-10 mg/dL) or less than 70 mg/dL.
- Conditions
- Ischemic Stroke, Transient Ischemic Attack, Atherosclerotic Stenosis
- Trial name
- TST (NCT01252875)
- Testing
- Target : 100 mg/dL (+/-10 mg/dL), 70 mg/dL
- Where
- 2 sites in France
- Volunteers
- 2,873 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atherosclerosis, Ischemia
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00617123
- Testing
- Vorapaxar 2.5 mg
- Volunteers
- 258 people
- Sponsor
- Merck Sharp & Dohme LLC
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947959
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Standard of care
- Where
- Germany
- Volunteers
- 665,533 people
- Sponsor
- Bayer